Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives $18.25 Consensus Target Price from Analysts

Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) have earned a consensus rating of “Moderate Buy” from the six analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $18.25.

Several research firms have issued reports on TRDA. Weiss Ratings restated a “sell (d)” rating on shares of Entrada Therapeutics in a research report on Friday, March 27th. Roth Mkm set a $10.00 price target on shares of Entrada Therapeutics in a research report on Friday, May 8th. Guggenheim upgraded shares of Entrada Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 11th. HC Wainwright lowered shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Finally, Wall Street Zen lowered shares of Entrada Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th.

Insider Activity at Entrada Therapeutics

In other news, COO Nathan J. Dowden sold 15,000 shares of Entrada Therapeutics stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $15.33, for a total transaction of $229,950.00. Following the sale, the chief operating officer directly owned 198,588 shares in the company, valued at approximately $3,044,354.04. The trade was a 7.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Kory James Wentworth sold 2,500 shares of Entrada Therapeutics stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $12.95, for a total transaction of $32,375.00. Following the sale, the chief financial officer owned 119,010 shares in the company, valued at approximately $1,541,179.50. This trade represents a 2.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 82,882 shares of company stock valued at $1,169,103. Company insiders own 9.49% of the company’s stock.

Institutional Trading of Entrada Therapeutics

Institutional investors have recently made changes to their positions in the business. State of Wyoming boosted its position in shares of Entrada Therapeutics by 130.9% during the 2nd quarter. State of Wyoming now owns 7,575 shares of the company’s stock valued at $51,000 after acquiring an additional 4,295 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Entrada Therapeutics by 72.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock valued at $51,000 after acquiring an additional 3,707 shares in the last quarter. Occudo Quantitative Strategies LP acquired a new stake in shares of Entrada Therapeutics during the 2nd quarter valued at about $68,000. IHT Wealth Management LLC acquired a new stake in shares of Entrada Therapeutics during the 2nd quarter valued at about $72,000. Finally, AXQ Capital LP acquired a new stake in shares of Entrada Therapeutics during the 3rd quarter valued at about $67,000. 86.39% of the stock is currently owned by institutional investors and hedge funds.

Entrada Therapeutics Price Performance

Shares of TRDA opened at $6.63 on Thursday. The company has a market capitalization of $257.38 million, a PE ratio of -1.66 and a beta of -0.09. Entrada Therapeutics has a one year low of $4.93 and a one year high of $16.45. The company’s fifty day moving average price is $11.16 and its 200 day moving average price is $10.87.

Entrada Therapeutics (NASDAQ:TRDA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.11. The company had revenue of $0.88 million for the quarter, compared to analyst estimates of $2.92 million. Entrada Therapeutics had a negative net margin of 2,895.05% and a negative return on equity of 51.22%. Analysts anticipate that Entrada Therapeutics will post -4.12 earnings per share for the current year.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.